Phase III trial of once-daily oral TDF and once-daily oral TDF/FTC (Kenya, Uganda)
In July, DSMB recommended placebo arm discontinue after early data showed daily oral TDF reduced HIV by an estimated 62 percent and daily oral TDF/FTC reduced HIV risk by an estimated 73 percent when compared to placebo.
Active trial arms are still ongoing and will provide additional data in 2012 and 2013.
Phase II trial of once-daily TDF/FTC (Botswana)
Analysis of the active and placebo arms indicated that daily oral TDF/FTC reduced the risk of HIV infection in both men and women participants by an estimated 62.6 percent compared to those who received the placebo.
*The trial end-dates listed in this table are estimates. Due to the nature of clinical trials the actual dates may change. AVAC will continue to monitor the trial's progress and will update the timeline accordingly.